Genetic Diagnosis and Treatment of Duchenne Muscular Dystrophy

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 25 May 2026 | Viewed by 628

Special Issue Editor


E-Mail
Guest Editor
The Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA
Interests: viral and non-viral gene therapies; neuromuscular and cardiovascular diseases

Special Issue Information

Dear Colleagues,

We are delighted to invite submissions for the Special Issue, “Genetic Diagnosis and Treatment of Duchenne Muscular Dystrophy”.

Duchenne muscular dystrophy (DMD) is one of the most common forms of muscular dystrophy, caused by mutations in the DMD gene encoding dystrophin protein, the deficiency or absence of which leads to progressive muscle weakness, cardiac and respiratory failure, and premature death. The DMD gene is the largest gene in the human genome with a highly diverse mutational profile that includes single and multiple exon duplications and deletions, as well as single-point and frameshift mutations that disrupt the dystrophin open reading frame. Over the past few decades, many therapeutic strategies have been developed and tested, some of which have received regulatory approval, and we expect that more will follow.

This Special Issue seeks to highlight advances in basic, translational, and clinical research to understand DMD at the molecular and structural levels. We welcome original research articles and reviews that highlight the development of meaningful therapies for DMD using cutting-edge technologies, biomarkers, and methods that standardize the functional outcome measures needed to assess therapeutic efficacy.

Original research articles and reviews will be considered for publication.

Dr. Liubov V. Gushchina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Duchenne muscular dystrophy
  • viral vectors
  • non-viral therapy
  • gene editing
  • common and rare mutations
  • biomarkers
  • methods of diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1189 KB  
Article
Brain Matters in Duchenne Muscular Dystrophy: DMD Mutation Sites and Their Association with Neurological Comorbidities Through Isoform Impairment
by Teodora Barbarii, Raluca Anca Tudorache, Dana Craiu, Elena Neagu, Lacramioara Aurelia Brinduse, Carmen Magdalena Burloiu, Catrinel Mihaela Iliescu, Magdalena Budisteanu, Ioana Minciu, Diana Gabriela Barca, Carmen Sandu, Oana Tarta-Arsene, Cristina Pomeran, Cristina Motoescu, Alice Dica, Cristina Anghelescu, Dana Surlica, Adrian Ioan Toma and Niculina Butoianu
Genes 2026, 17(1), 12; https://doi.org/10.3390/genes17010012 - 24 Dec 2025
Abstract
Background: Duchenne/Becker muscular dystrophy (DMD/BMD) is associated with a wide spectrum of brain-related comorbidities. Methods: This retrospective study assesses the neuropsychiatric profile of DMD/BMD patients and the hypothesis of a functional-versus-structural approach of dystrophin gene variants/impaired isoforms in relation to brain comorbidities. Patients with documented [...] Read more.
Background: Duchenne/Becker muscular dystrophy (DMD/BMD) is associated with a wide spectrum of brain-related comorbidities. Methods: This retrospective study assesses the neuropsychiatric profile of DMD/BMD patients and the hypothesis of a functional-versus-structural approach of dystrophin gene variants/impaired isoforms in relation to brain comorbidities. Patients with documented mutation in the DMD gene and neuropsychiatric assessments were included. Seven comorbidities were analyzed based on variant location and dystrophin brain isoform disruption. The clustering of comorbidities and genotype–phenotype correlations were studied. Results: 264 DMD/BMD patients met inclusion criteria. 22 variants have never been described before. A high prevalence of neuropsychiatric comorbidities was identified in the cohort with higher values in patients with distal mutations. The number of comorbidities increased with the number of brain dystrophin isoforms predicted to be lost. Functional-versus-structural comparison revealed that Dp140 5′UTR variants might not affect protein expression. Epilepsy and intellectual disability (ID) showed significant association in this cohort. Neuropsychiatric phenotype varied greatly in patients with identical variants, even between siblings. Conclusions: This is one of the largest European cohorts for which all these comorbidities were studied in association with DMD gene mutation site and the first study of this kind performed on the Eastern European DMD/BMD population. Our group analyzed, for the first time, Dp140 5′UTR variants in relation to all neuropsychiatric phenotypes and showed that epilepsy and ID are strongly associated in DMD/DMB patients. Full article
(This article belongs to the Special Issue Genetic Diagnosis and Treatment of Duchenne Muscular Dystrophy)
Show Figures

Figure 1

11 pages, 207 KB  
Article
Duchenne Muscular Dystrophy in the Republic of North Ossetia–Alania: Epidemiological Study, Diagnostic Issues, and Treatment Prospects
by Rena Zinchenko, Inna Tebieva, Aysylu Murtazina, Sofya Ionova, Alisa Zhmurova-Kriventsova, Olga Shchagina, Elena Zinina, Yulia Gabisova, Alana Khokhova, Marina Tokazova, Murat Ikaev, Oleg Remizov, Sofia Popovich, Ludmila Kuzenkova, Andrey Marakhonov and Sergey Kutsev
Genes 2025, 16(12), 1458; https://doi.org/10.3390/genes16121458 - 6 Dec 2025
Viewed by 280
Abstract
Background/Objectives: The article presents data on Duchenne muscular dystrophy (DMD) in the Republic of North Ossetia-Alania (RNOA), describing the population characteristics of the disease among children in RNOA (2006–2023). Methods: The number of newborns was 172,115, with 86,057 boys from 2006 to 2023. [...] Read more.
Background/Objectives: The article presents data on Duchenne muscular dystrophy (DMD) in the Republic of North Ossetia-Alania (RNOA), describing the population characteristics of the disease among children in RNOA (2006–2023). Methods: The number of newborns was 172,115, with 86,057 boys from 2006 to 2023. During the reporting period, 19 families (23 patients, including 22 boys) were identified. The molecular and genetic characteristics of the patients were analyzed throughout the entire observation period, which began in 1998. Results: The prevalence of the disease was 1:3912 among newborn boys (95%CI: 1:2584–1:6242), which is slightly higher than in other regions of the Russian Federation (RF) and most countries around the world. The spectrum of DMD genetic variants in RNOA aligns with worldwide patterns but reveals differences in frequencies compared to RF data. The frequency of exon deletions in the DMD gene range from 65.0 to 70.0% (60% in RNOA vs. <50% in RF) worldwide, for duplications—9.0–11.0% globally (16% in RNOA), and for nonsense variants—9.7–26.5% worldwide (20% in RNOA). Twelve patients (41.0%) in RNOA qualified for therapy, and Translarna was prescribed in most cases. In the cohort of children, one girl was identified with classic DMD, confirmed by genetic studies. Different limitations of the study were hindered by the small cohort size, patients’ remote residences, and poor therapy compliance of our patients. Conclusions: The heterogeneity of mutation spectrum across different populations underscores the influence of ethnic background. Consequently, this study highlights the importance of population-specific studies for improving DMD care. Full article
(This article belongs to the Special Issue Genetic Diagnosis and Treatment of Duchenne Muscular Dystrophy)
Back to TopTop